Metabolic dysfunction-associated steatotic liver disease and its link to cancer
M Kalligeros, L Henry, ZM Younossi - Metabolism, 2024 - Elsevier
Metabolic-dysfunction associated steatotic liver disease (MASLD), formerly known as
nonalcoholic fatty liver disease (NAFLD), is a growing global health concern with significant …
nonalcoholic fatty liver disease (NAFLD), is a growing global health concern with significant …
Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis …
P Danpanichkul, K Suparan, P Dutta, C Kaeosri… - Metabolism, 2024 - Elsevier
Objective Metabolic dysfunction-associated steatotic liver disease (MASLD) and
cardiometabolic conditions affect populations across economic strata. Nevertheless, there …
cardiometabolic conditions affect populations across economic strata. Nevertheless, there …
Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma
Y Wang, JS Fleishman, T Li, Y Li, Z Ren… - Frontiers in …, 2024 - frontiersin.org
In light of a global rise in the number of patients with type 2 diabetes mellitus (T2DM) and
obesity, non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction …
obesity, non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction …
Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria
Introduction The 2023 nomenclature defined criteria for steatotic liver disease (SLD),
including metabolic dysfunction-associated SLD (MASLD), alcohol-associated liver disease …
including metabolic dysfunction-associated SLD (MASLD), alcohol-associated liver disease …
Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake
Abstract Background and Aim Metabolic dysfunction‐associated steatotic liver disease
(MASLD) has become a leading cause of chronic liver disease worldwide. A new entity …
(MASLD) has become a leading cause of chronic liver disease worldwide. A new entity …
Waitlisting and liver transplantation for MetALD in the United States: an analysis of the UNOS national registry
Conclusions: We developed and validated an algorithm for identifying SLD phenotypes in
UNOS. MetALD is the third leading etiology among those waitlisted and underwent …
UNOS. MetALD is the third leading etiology among those waitlisted and underwent …
Weight-adjusted waist index is positively and linearly associated with all-cause and cardiovascular mortality in metabolic dysfunction-associated steatotic liver disease …
W Liu, X Yang, T Zhan, M Huang, X Tian… - Frontiers in …, 2024 - frontiersin.org
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most
common chronic liver disease. Body mass index (BMI) is the most used obesity index but …
common chronic liver disease. Body mass index (BMI) is the most used obesity index but …
Current Burden of Steatotic Liver Disease and Fibrosis among Adults in the United States, 2017-2023
Methods Using the recent National Health and Nutrition Examination Survey from 2017 to
2023, we analyzed data from 12,199 participants (≥ 18 years) who completed transient …
2023, we analyzed data from 12,199 participants (≥ 18 years) who completed transient …
Polyribonucleotide nucleotidyltransferase 1 participates in metabolic-associated fatty liver disease pathogenesis by affecting lipid metabolism and mitochondrial …
C Guan, X Zou, C Yang, W Shi, J Gao, Y Ge, Z Xu… - Molecular …, 2024 - Elsevier
Objective Metabolic-associated fatty liver disease (MAFLD) represents one of the most
prevalent chronic liver conditions worldwide, but its precise pathogenesis remains unclear …
prevalent chronic liver conditions worldwide, but its precise pathogenesis remains unclear …
Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States
S Gawrieh, E Vilar‐Gomez, TA Woreta… - Alimentary …, 2024 - Wiley Online Library
Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) has recently
been proposed as a replacement term for NAFLD. Aims To assess the effects of this new …
been proposed as a replacement term for NAFLD. Aims To assess the effects of this new …